Acoustic wave therapy is over 30 years old and was first used in medicine for the treatment of kidney stones (lithotripsy). Acoustic waves are the standard of care worldwide for stones, pain pathologies, and bone healing. It is a thoroughly researched technology, and it is considered non-significant risk when used for the majority of indications. TRT’s patented, FDA 510(k) cleared unfocused acoustic waves, known as SoftWaves®, produce both positive and negative (Tensile) forces on cells. Our probe generates waves that affect cells within a two inch diameter. Though all of the cells in this target area are exposed, only pathologic tissue reacts.
Cells are used to being exposed to many forces, however, the combination of simultaneous positive and negative forces puts shearing forces on the cell membrane. The shearing forces momentarily make the membranes permeable while still keeping the cell intact. During this duration of permeability, certain proteins and, more importantly, small pieces of RNA are ejected from the cell into the surrounding tissue.
Neighboring cells sense this RNA release via cellular receptors known as toll-like receptor 3 (TLR3). These receptors are activated by RNA pieces released when nearby cells are damaged or die. SoftWave® treatment, however, triggers TLR3 without damaging cells but rather by just making cells’ membranes temporarily permeable. SoftWaves fool the body into thinking an injury has occurred, and we initiate the natural biologic process of repair.
​
Four to eight weeks after patients’ first SoftWave® treatment, we see up to a 400% increase in blood vessels (small, medium, and large). We also see a corresponding increase in permanent blood supply, which helps in fighting infections.  Consequently, bacteria counts drop dramatically, and biofilms that protect bacteria colonies are destroyed. Immediately following treatment, there is a reduction in pain, swelling, and inflammation. Controlling the inflammatory response is critical in spine injury patients, as the swelling often destroys the remaining functional spinal cord post injury. In the battle against autism, controlling the inflammatory and immune response is also thought to be key.​
TLR3 is known to control both the immune and inflammatory response of the cells as well as to initiate the biologic cascade associated with tissue regeneration or repair. Soon after the TLR3 receptors are activated, stem cell attractants are produced. Within hours, stem cells begin arriving from neighboring tissue but more importantly from bone marrow, where many stem cells reside in wait until needed. The stem cells produce original tissue, not scar tissue, and can even remodel existing scar tissue as a result of the call sent out after the TLR3 were activated. For example, with our client Ross Mason,(right) we were able to recover the use of his diaphragm over 6 years after injury. Almost like a reset button, acoustic wave therapy positively influences the autonomic nervous system.
​
SoftWave® therapy has also been proven to drastically reduce apoptosis (programmed cell death) post trauma. This is important in the treatment of spine patients immediately post injury, as the organized cellular destruction initiated by the body (apoptosis) can be minimized.
​
Our research partners in Austria have just proved that Softwave treatment also communicates with cells via toll-like receptor 4 (TLR4). Although not yet understood by researchers, the commonality among neurological disorders, including autism, is that the TLR4 receptors are over activated, causing havoc in neurologic tissues. Our research partners have shown that Softwave treatment can in fact turn off these TLR4 receptors, which could be potentially groundbreaking for neurological pathologies.
All of these positive biologic responses are critical to many pathologies that affect millions of patients.  Every process described above is supported by our research and publications in high level journals at world renowned institutions.
Ross Mason was injured in a bicycle accident in August of 2007

Read About Our Product Lines

TRT currently has product lines developed for the treatment of six distinct areas of care:

CardioGold – Cardiac and vascular indications
LithoGold – Lithotripsy and urology indications
OrthoGold – Orthopedic indications
VetGold – Veterinary indications
DermaGold – Wound care indications

Each of these devices has successfully undergone CE approval. TRT has the rights to distribute the products throughout North America, and MTS has the rights to distribute in all other locations. TRT currently has approval to distribute two devices in the United States: the LithoGold and VetGold systems. In Canada, TRT is approved to distribute the LithoGold, DermaGold, and VetGold systems, along with specific products in its OrthoGold line.